Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
INCY Stock Forecast 2025-2026
$95.17
Current Price
$18.67B
Market Cap
Buy 12
Hold 11
Sell 2
Wall St Analyst Ratings
Distance to INCY Price Targets
+35.5%
To High Target of $129.00
+2.4%
To Median Target of $97.50
-26.4%
To Low Target of $70.00
INCY Price Momentum
-5.3%
1 Week Change
-12.0%
1 Month Change
+31.3%
1 Year Change
+37.8%
Year-to-Date Change
-12.9%
From 52W High of $109.28
+77.7%
From 52W Low of $53.56
📊 TOP ANALYST CALLS
Did INCY Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Incyte is one of their latest high-conviction picks.
Latest INCY Stock Price Targets & Analyst Predictions
Based on our analysis of 39 Wall Street analysts, INCY has a neutral consensus with a median price target of $97.50 (ranging from $70.00 to $129.00). The overall analyst rating is Buy (7.4/10). Currently trading at $95.17, the median forecast implies a 2.4% upside. This outlook is supported by 12 Buy, 11 Hold, and 2 Sell ratings.
Conversely, the most conservative target is provided by Leonid Timashev at RBC Capital, suggesting a 26.4% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
INCY Analyst Ratings
12
Buy
11
Hold
2
Sell
INCY Price Target Range
Low
$70.00
Average
$97.50
High
$129.00
Current: $95.17
Latest INCY Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for INCY.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 8, 2025 | Morgan Stanley | Vikram Purohit | Equal-Weight | Maintains | $92.00 |
| Dec 8, 2025 | Wells Fargo | Derek Archila | Overweight | Maintains | $116.00 |
| Dec 8, 2025 | Mizuho | Salim Syed | Outperform | Upgrade | $121.00 |
| Nov 24, 2025 | Barclays | Etzer Darout | Overweight | Maintains | $115.00 |
| Nov 4, 2025 | Piper Sandler | Allison Bratzel | Overweight | Maintains | $102.00 |
| Nov 3, 2025 | Guggenheim | Michael Schmidt | Buy | Upgrade | $125.00 |
| Oct 29, 2025 | Truist Securities | Srikripa Devarakonda | Hold | Reiterates | $93.00 |
| Oct 29, 2025 | RBC Capital | Brian Abrahams | Sector Perform | Maintains | $84.00 |
| Oct 29, 2025 | Wells Fargo | Derek Archila | Overweight | Maintains | $97.00 |
| Oct 29, 2025 | Barclays | Peter Lawson | Overweight | Maintains | $101.00 |
| Oct 9, 2025 | JP Morgan | Jessica Fye | Neutral | Maintains | $89.00 |
| Sep 24, 2025 | RBC Capital | Brian Abrahams | Sector Perform | Maintains | $81.00 |
| Sep 22, 2025 | Stifel | Stephen Willey | Buy | Maintains | $115.00 |
| Sep 19, 2025 | Guggenheim | Michael Schmidt | Neutral | Reiterates | $N/A |
| Sep 4, 2025 | B of A Securities | Tazeen Ahmad | Buy | Maintains | $104.00 |
| Aug 22, 2025 | JP Morgan | Jessica Fye | Neutral | Maintains | $73.00 |
| Aug 6, 2025 | Wells Fargo | Derek Archila | Overweight | Upgrade | $89.00 |
| Aug 1, 2025 | Barclays | Luke Sergott | Overweight | Initiates | $90.00 |
| Jul 30, 2025 | RBC Capital | Brian Abrahams | Sector Perform | Maintains | $72.00 |
| Jul 30, 2025 | Citigroup | David Lebowitz | Buy | Maintains | $103.00 |
Incyte Corporation (INCY) Competitors
The following stocks are similar to Incyte based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Incyte Corporation (INCY) Financial Data
Incyte Corporation has a market capitalization of $18.67B with a P/E ratio of 16.2x. The company generates $4.81B in trailing twelve-month revenue with a 24.7% profit margin.
Revenue growth is +20.0% quarter-over-quarter, while maintaining an operating margin of +31.6% and return on equity of +30.4%.
Valuation Metrics
Market Cap
$18.67B
Enterprise Value
$16.10B
P/E Ratio
16.2x
PEG Ratio
0.1x
Price/Sales
3.9x
Growth & Margins
Revenue Growth (YoY)
+20.0%
Gross Margin
+92.8%
Operating Margin
+31.6%
Net Margin
+24.7%
EPS Growth
+298.4%
Financial Health
Cash/Price Ratio
+15.7%
Current Ratio
3.2x
Debt/Equity
0.9x
ROE
+30.4%
ROA
+13.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Incyte Corporation (INCY) Business Model
About Incyte Corporation
What They Do
Biopharmaceutical company focused on innovative therapeutics.
Business Model
Incyte Corporation operates by discovering, developing, and commercializing therapeutic drugs primarily in oncology and inflammation. The company generates revenue through the sale of its proprietary products, such as its flagship cancer treatment, and by forming strategic partnerships with other pharmaceutical companies to enhance research and development efforts.
Additional Information
Incyte has a strong commitment to research and development, maintaining a diverse pipeline of next-generation treatments in clinical trials. The company is headquartered in Wilmington, Delaware, and plays a significant role in advancing medical science and improving patient care.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
2,617
CEO
Mr. Herve Hoppenot
Country
United States
IPO Year
1993
Website
www.incyte.comIncyte Corporation (INCY) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Incyte's Rare Blood Cancer Therapy Gets FDA's Breakthrough Status
INCY secures FDA Breakthrough Therapy status for INCA033989 after early data show rapid and sustained platelet normalization in essential thrombocythemia patients.
Dec 08, 2025
By Zacks Equity Research
Analyst Blog
Latest News
Quick Summary
INCY has received FDA Breakthrough Therapy designation for INCA033989, showing promising early results in normalizing platelets for essential thrombocythemia patients.
Why It Matters
FDA Breakthrough Therapy status can accelerate drug development and approval, potentially leading to increased revenue for INCY. Positive early data enhances market confidence and may boost stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Incyte's INCA033989, a first-in-class monoclonal antibody for ET, showed updated positive data at ASH 2025, reinforcing its potential in treatment.
Why It Matters
Positive data on Incyte's INCA033989 enhances its market potential, signaling potential growth and profitability, which could impact stock performance and investor confidence.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
The Investment Committee is currently discussing the latest Calls of the Day, which may influence investment strategies and decisions.
Why It Matters
Debates on Calls of the Day can signal potential shifts in investment strategies or market sentiment, impacting stock performance and influencing investor decisions.
Source: CNBC Television
Market Sentiment:
Neutral
Quick Summary
The FDA has granted Breakthrough Therapy status to Incyte's treatment for a rare blood cancer, with Incyte stock trading near five-year highs.
Why It Matters
FDA Breakthrough Therapy status can accelerate a drug's development and approval, potentially increasing Incyte's market value and investor confidence, as reflected in its stock performance.
Source: Investors Business Daily
Market Sentiment:
Positive
Quick Summary
Incyte Corporation (INCY) presented data on mutCALR and advancements in therapies for myeloproliferative neoplasms at the ASH conference.
Why It Matters
Incyte's discussion on mutCALR data highlights potential advancements in treating myeloproliferative neoplasms, which could impact drug efficacy, market share, and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Incyte's monoclonal antibody, INCA033989, targeting mutCALR, has received Breakthrough Therapy Designation from the U.S. FDA.
Why It Matters
Incyte's breakthrough therapy designation for INCA033989 could accelerate its development and approval, potentially boosting revenue and stock performance, signaling strong growth prospects.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About INCY Stock
What is Incyte Corporation's (INCY) stock forecast for 2026?
Based on our analysis of 39 Wall Street analysts, Incyte Corporation (INCY) has a median price target of $97.50. The highest price target is $129.00 and the lowest is $70.00.
Is INCY stock a good investment in 2026?
According to current analyst ratings, INCY has 12 Buy ratings, 11 Hold ratings, and 2 Sell ratings. The stock is currently trading at $95.17. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for INCY stock?
Wall Street analysts predict INCY stock could reach $97.50 in the next 12 months. This represents a 2.4% increase from the current price of $95.17. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Incyte Corporation's business model?
Incyte Corporation operates by discovering, developing, and commercializing therapeutic drugs primarily in oncology and inflammation. The company generates revenue through the sale of its proprietary products, such as its flagship cancer treatment, and by forming strategic partnerships with other pharmaceutical companies to enhance research and development efforts.
What is the highest forecasted price for INCY Incyte Corporation?
The highest price target for INCY is $129.00 from at , which represents a 35.5% increase from the current price of $95.17.
What is the lowest forecasted price for INCY Incyte Corporation?
The lowest price target for INCY is $70.00 from Leonid Timashev at RBC Capital, which represents a -26.4% decrease from the current price of $95.17.
What is the overall INCY consensus from analysts for Incyte Corporation?
The overall analyst consensus for INCY is neutral. Out of 39 Wall Street analysts, 12 rate it as Buy, 11 as Hold, and 2 as Sell, with a median price target of $97.50.
How accurate are INCY stock price projections?
Stock price projections, including those for Incyte Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 11, 2025 3:10 AM UTC